Medicus Pharma Narrows SkinJect Focus to Gorlin Syndrome After FDA Feedback — Medicus Pharma Ltd.

Event summary

Medicus Pharma will focus SkinJect® development exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions, abandoning further work in sporadic/nodular BCC.
The decision follows a commercial assessment, clinical input from Babar K. Rao, MD, and feedback from the FDA's Office of Orphan Products Development.
FDA feedback suggested BCC in Gorlin syndrome is not distinct enough from sporadic BCC for orphan-drug designations, but left regulatory pathways open.
The Gorlin-focused strategy targets a U.S. market of ~11,000 patients and $1.1B in potential revenue, per an independent commercial assessment.

The big picture

Medicus is doubling down on a capital-efficient strategy, prioritizing high-risk-adjusted opportunities in rare diseases. The Gorlin syndrome focus aligns with broader biotech trends favoring precision therapies for underserved patient populations. The move also reflects growing scrutiny of orphan-drug designations, as regulators push back on subset claims. With ~$383M in potential peak revenue, SkinJect® could become a key growth driver if clinical and regulatory hurdles are cleared.

What we're watching

Regulatory Pathways: Whether Medicus can secure Orphan Drug or Rare Pediatric Disease designations despite FDA's initial skepticism.
Clinical Execution: The pace at which the NDA-enabling SKNJCT-005 study progresses in Gorlin syndrome patients.
Commercial Viability: How payers and physicians respond to a rare-disease-anchored pricing model of ~$25,800 per treatment.